Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Chief Business Officer
Company: CStone Pharmaceuticals
个人简介:
Dr. Bing Yuan is currently Chief Strategy & Business Officer at CStone Pharmaceuticals. As a seasoned business executive in business development and commercial strategy, he has made significant contributions to 12 global oncology brands at various stages. He is currently responsible for corporate strategy, business development & alliance management, portfolio strategy & business insights, and R&D project management office at CStone. Previously, he had also established and managed a few other functions, including investor relations, government affairs, communications & PR, medical affairs and commercial team.  Before joining CStone in 2016, he was Executive Director and Global Lead of Oncology BD at Merck (MSD). He focused on expanding Merck's leadership position in cancer immunotherapy, and successfully achieved 34 M&A, licensing and Keytruda collaboration deals. Before Merck, he was Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, responsible for Glivec and Afinitor brand life cycle strategy. He played a key role in global launch of Zykadia in ALK+ lung cancer and was a core deal team member for Jakavi, Mektovi and Tabrecta licensing deals. He was three-time Novartis Oncology President Award recipient. He also served as Global Oncology Marketing Lead at Eisai in the past, managing entire oncology portfolio. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Chairman & CEO
Company: CARsgen Therapeutics, Ltd
个人简介:
Zonghai Li M.D., Ph.D., is dedicated himself to develop innovative treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become the most widely used unnatural peptide in antitumor study now. He is the inventor of many new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; Run-CAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Vice President, Head of Business Development
Company: Akeso Biopharma Inc.
个人简介:
Dr. Chen Chen (Michael) has joined Akeso as Vice President in July, 2020 and leads Akeso business development.Before joining Akeso, Dr. Chen Chen (Michael) worked as Head of External Innovation APAC for Merck KGaA.  With alignment of Merck global R&D focus, Dr. Chen led collaborations with local pharmaceutical/biotech companies, investor groups and academic institutions in China and APAC areas. He encompassed scouting and evaluation of external opportunities including therapeutic assets (from discovery to clinical PoC stages), new drug targets/biomarkers, and novel discovery technologies.  He was also responsible for Merck global BD activities to leverage companies in China/APAC regions for Merck’s internalization and externalization opportunities at different R&D stages.  This particularly
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: VP, Head of R&D and Chief Medical Officer
Company: SciClone Pharmaceuticals
个人简介:
Dr. Xiaoning Guo is currently the vice President, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals co., LTD. He is fully responsible for R&D of pipeline drug candidates and life cycle management of post-market products. Dr. Guo graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with a PhD in pharmacology. Later, he went to the United States and worked as a research affiliate at Roswell Park Cancer Institute, a National Comprehensive Tumor Hospital and Cancer Center. In 2007, Dr. Guo came back to China and joined MNCs including Astrazeneca and Johnson & Johnson to in charge of translational medicine project, clinical Phase I to III project development and portfolio management. After a couple of years, Dr. Guo joined Covance as a senior Director, Clinical Drug Development Leader in Asia Pacific region, responsible for the development and implement of the global development strategy of the project. Dr. Guo has accumulated extensive experience in different stages of drug development from preclinical including biomarker research to translational medicine to clinical development. Before joining SciClone, Dr. Guo served as deputy General Manager and Chief Medical Officer of General Regeneratives, co., Ltd., responsible for clinical development and regulatory affairs department.